Whit Bernard

Mr. Bernard is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as a managing member of Population Health Partners GP, LLC, its General Partner. Mr. Bernard previously served as Vice Chairman and Managing Partner of Population Health Partners, L.P. from May 2020 to September 2024.

Since September 2024, Whit has served as Chief Executive Officer of Metsera, Inc., a clinical-stage biotechnology company focused on developing best-in-class, next-generation therapeutics to treat overweight and obesity founded by PHP and ARCH Ventures. Before being promoted to CEO, he served as Metsera’s Chief Operating Officer from March 2023 while also being a managing partner at PHP.

Prior to co-founding Population Health Partners, Whit Bernard was Senior Vice President of Commercial Strategy and Business Development at The Medicines Company, where he had responsibility for corporate strategy and go-to-market planning. He also oversaw a global business development process which resulted in the sale of the company for $9.7 billion in January 2020. Subsequent to the closing of that transaction, Whit co-led the integration of The Medicines Company into Novartis.

Prior to his role at The Medicines Company, Whit was an Associate Partner at McKinsey & Company, where he co-led a strategic service line for small cap clinical-stage biotechs, advised major pharmaceutical companies on innovative commercial models, and supported the creation of several private equity-sponsored strategies in the life sciences.

In association with Population Health Partners, Whit serves as a board observer at New Amsterdam Pharma.

Earlier in his career, Whit studied musicology as a Fulbright Scholar and helped launch a leading contemporary music nonprofit. He has an MBA with Honors from the Kellogg School of Management, and BA summa cum laude in music from Brown University.